The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fFocEQ
via IFTTT
0 comments:
Post a Comment